劳拉替尼 lorlatinib

Drug Class

Third-generation ALK tyrosine kinase inhibitor

Mechanism

Inhibits ALK and ROS1 tyrosine kinases, designed to cross the blood-brain barrier and overcome resistance mutations that develop during treatment with first- and second-generation ALK inhibitors.

Approved Indication

Treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive.

What This Means For Patients

劳拉替尼 is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2018) — Sources
• EMA — Approved (2019) — Sources
• NMPA — Approved (2022) — Sources

Pivotal Clinical Evidence

• CROWN — Shaw et al., N Engl J Med 2020 (NCT03052608) — Sources

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210868s003lbl.pdf
• https://www.ema.europa.eu/en/medicines/human/EPAR/lorviqua
• https://www.nmpa.gov.cn/